“…The technology is based on genetically linking a short peptide or small protein domain to either the aminoor carboxy-terminus of the target protein and then using the fusion tag to facilitate efficient capture and purification of the chimeric protein on an affinity matrix. Certain fusion partners such as the maltose binding protein (MBP) (di Guan et al, 1988), carbohydrate binding modules (CBMs) (Ahn et al, 2004;Murashima et al, 2003), thioredoxin (Trx) (LaVallie et al, 1993), and the Escherichia coli protein N-utilizing substance A (NusA) (Davis et al, 1999), have been shown to improve product solubility and expression by stabilizing the mRNA (Makrides, 1996) or by providing a psuedo-chaperone effect (Samuelsson et al, 1994). Fusion tags have also been used to increase in vivo proteolytic stability (Jansson et al, 1990;Martinez et al, 1995;Staahl and Nygren, 1997), to serve as effective expression and localization reporters (Gerdes and Kaether, 1996;Ozawa, 2006), and, when combined with their corresponding leader peptide, to control product localization in or secretion from the expression host (Ford et al, 1991;Johnson et al, 1992;Uhlen and Moks, 1990).…”